Want to see AU:CMP full AI Analyst Report?
CMP Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.22 - AU$0.45
Previous CloseN/A
Volume3.00K
Average Volume (3M)75.89K
Market Cap
AU$45.95M
Enterprise ValueAU$59.50
Total Cash (Recent Filing)AU$6.15M
Total Debt (Recent Filing)AU$14.11M
Price to Earnings (P/E)218.2
Beta0.88
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding199,761,750
10 Day Avg. Volume42,139
30 Day Avg. Volume75,888
Financial Highlights & Ratios
PEG Ratio-2.23
Price to Book (P/B)2.40
Price to Sales (P/S)0.91
P/FCF Ratio8.49
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.02
Revenue Forecast (FY)AU$75.60M
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSustained revenue expansion indicates growing demand for Compumedics’ diagnostic systems across sleep and neurological applications. Continued top-line growth can support a larger installed base, more follow-on software and service revenue, and stronger operating leverage as the business scales.
Resilient Gross MarginsA durable gross margin in the low-to-mid 50% range suggests the company retains meaningful value from its products despite changes in revenue mix. This provides a foundation for funding research, sales support, and service capabilities while leaving room for profitability to improve.
Improved Cash GenerationThe strong 2026 cash-flow rebound shows that the business can generate substantial cash when operating and working-capital performance improve. Free cash flow nearly matched reported earnings, providing greater capacity to support investment, debt servicing, and ongoing operations.
Bears Say
Thin Net ProfitabilityVery thin net profitability leaves limited protection against cost increases, weaker demand, or execution setbacks. Even with revenue growth and improving operating performance, the company currently converts only a small portion of sales into earnings, constraining internally funded expansion.
Volatile Cash ConversionThe sharp variation in annual cash flow indicates that the latest improvement has not yet demonstrated consistent cash conversion across business conditions. Volatility can complicate investment planning and reduce financial flexibility if operating performance weakens again over the next several quarters.
Weak Shareholder ReturnsPersistently weak return on equity shows that the company has not yet translated its capital base into strong, consistent earnings power. This limits the effectiveness of reinvestment and signals that further revenue growth must be accompanied by better margins and operating discipline.
Compumedics Limited News
CMP FAQ
What was Compumedics Limited’s price range in the past 12 months?
Compumedics Limited lowest share price was AU$0.21 and its highest was AU$0.45 in the past 12 months.
What is Compumedics Limited’s market cap?
Compumedics Limited’s market cap is AU$45.95M.
When is Compumedics Limited’s upcoming earnings report date?
Compumedics Limited’s upcoming earnings report date is Mar 04, 2027 which is in 153 days.
How were Compumedics Limited’s earnings last quarter?
Compumedics Limited released its earnings results on Aug 24, 2026. The company reported AU$0 earnings per share for the quarter.
Is Compumedics Limited overvalued?
According to Wall Street analysts Compumedics Limited’s price is currently Overvalued.
Does Compumedics Limited pay dividends?
Compumedics Limited does not currently pay dividends.
What is Compumedics Limited’s EPS estimate?
Compumedics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Compumedics Limited have?
Compumedics Limited has 199,761,750 shares outstanding.
What happened to Compumedics Limited’s price movement after its last earnings report?
Compumedics Limited reported an EPS of AU$0 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Compumedics Limited?
Currently, no hedge funds are holding shares in AU:CMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compumedics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-12.72%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
5.41%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Compumedics Limited
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Technical Analysis
Somnomed Limited
―
HeraMED Ltd.
―
EMvision Medical Devices Ltd.
―
4DMedical Ltd
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―







